VCHRI profile on Drs. Rennie and Cherkasov

Date Posted: 
Drs Rennie and Cherkasov
VCHRI News published an article today discussing Drs. Rennie and Cherkasov's novel approach to developing new drugs to fight prostate cancer, and their team research approach. The VCHRI story includes a link to their article in Cancer Letters 437:35-43 (28 Nov 2018). We thank the funding agencies that supported this research: Canadian Institutes of Health Research, Prostate Cancer Canada, and the Terry Fox Research Institute.  You can read the original article here; in addition, the text is included below.


Prostate cancer is the most common cancer in men. While incidences of the disease are declining, roughly 21,000 Canadian men are still diagnosed each year, with 1 in 29 cases taking an aggressive and deadly form. At the Vancouver Prostate Centre (VPC), Vancouver Coastal Health Research Institute scientists, Dr. Artem Cherkasov and Dr. Paul Rennie are combining teamwork and state-of-the art technology to try to bring those numbers down. In their work they focus on the androgen receptor (AR)–a protein that is regulated by male hormones and represents one of the main drivers of prostate cancer.

"Prostate cancer tumours need androgen receptors to live and progress. If you can shut down these receptors you can eliminate prostate cancer."

Using a computer modelling system that can scan a database of hundreds of millions of molecules, Cherkasov develops virtual anti-AR drug candidates. Then, if they have good potential, he hands them over to Rennie for real-life experimental evaluation. “We first discuss which area of the AR protein to focus in on,” says Rennie. “Art brings the hammer and I tell him where to hit. It is a great partnership.”

Over the years, countless anti-AR drugs have been developed to attack what appears to be a simple, single target. But it is far from simple—AR is incredibly drug-resistant. It mutates rapidly and in the case of progressive prostate cancer, it learns how to outmanoeuvre new drug therapies very quickly.

“It’s like whack-a-mole,” says Rennie. “You hit it down, but it pops up again. In the interim the patient gets several months to a year or so. But it comes back.” In some patients, the mutated AR is even able to use the drug to accelerate cancer growth. 

“We know that AR is very capable of mutating. Everything that is on the market has already been countered by those mutations. We hope to bypass that stage.”


Current anti-AR drugs typically target AR at its early stage of activation, which is a complex and multi-step process. So Rennie and Cherkasov are shifting the timeline. The team has designed a drug compound to attack AR at a later stage of its activation in a cell, called dimerization. Dimerization is when two AR proteins are joined to then become a fully activated AR complex. It is only after this dimerization stage that AR becomes a driver of various biological process including those that regulate the development of prostate cancer.

“No one else has been able to address this stage before,” says Cherkasov. “Using our technology, we are the first to try and target that downstream step. Our approach is showing good results in initial in vitro experiments.” 

This new drug prototype also targets a different region of the AR protein than other anti-AR drugs. Rennie calls it the ‘business end’ of the AR, a core region crucial to the protein’s survival and therefore less likely to mutate and cause more aggressive cancer. 

“That’s the beauty of it; it can potentially be applicable for even the hard-to-treat cases.  And, theoretically, this drug could shrink existing tumours as well as prevent the growth of new ones.” 

Cherkasov says having access to the right tools has given his team the leading edge in prostate cancer research—without the aid of his computer models at VPC, he would not have been able to find and target this region of the AR protein. The team plans to move on to pre-clinical testing in the next six months, and hopes for clinical trials of the dimerization compound within two to three years. A summary of their findings is published in the latest edition of Cancer Letters.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.


Conference Flyer Page 1

Breast & Prostate Cancer half-day virtual conference: Saturday, September 18th, 2021

The What you Need to Know for Your Patients Post Breast & Prostate Cancer Conference, taking place online on Saturday, September 18th, 2021 from 8:00am – 1:30pm, is an accredited virtual half-day conference focusing on screening, treatment, side-effect management & emerging new therapies for breast & prostate cancer patients. Click here for more information and to register. 

Dr. Peter Black, team captain

Terry Fox Run fundraiser: September 19th, 2021

The 41st Annual Terry Fox Run is taking place on Sunday September 19, 2021. If you are able, please consider donating to our team (tax receipts issued), raising funds for the Terry Fox Foundation's ground-breaking cancer research. 


Work at the Vancouver Prostate Centre

Wednesday, September 8, 2021

Recent publication proposes a potential new therapeutic approach to treatment-resistant prostate cancer

Tuesday, August 3, 2021

Dr. Cherkasov receives 2021 Faculty of Medicine Distinguished Achievement Award

Dr. Cherkasov